Moxifloxacina Anfarm

Moxifloxacin, the active ingredient in Moxifloxacina Anfarm, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections in adult patients, including pneumonia, sinusitis, bronchitis exacerbations, and complicated skin or intra‑abdominal infections.

GNH USA supplies Moxifloxacina Anfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat bacterial infections in the respiratory, skin and abdominal systems. - Community‑acquired pneumonia: achieves bacterial eradication and clinical recovery. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Acute bacterial exacerbation of chronic bronchitis: improves lung function and resolves bacterial load. - Complicated skin and skin‑structure infections: eliminates pathogenic bacteria and promotes wound healing. - Complicated intra‑abdominal infections: provides systemic antibacterial activity against mixed flora.

Moxifloxacin may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertiginous sensation. - Rash: mild skin erythema. - Elevated liver enzymes: transient hepatic enzyme rise.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon pain or rupture, especially in the Achilles. - QT interval prolongation: risk of cardiac arrhythmias. - Clostridioides difficile infection: severe colitis. - Severe allergic reactions: anaphylaxis, angioedema. - Hepatic failure: marked liver dysfunction. - Seizures: rare neurologic events.

Before initiating therapy, clinicians should consider several safety measures. - Assess renal function: adjust therapy if renal impairment is present. - Monitor for tendon pain: discontinue if signs of tendonitis or rupture appear. - Avoid concomitant QT‑prolonging drugs: reduce risk of arrhythmia. - Use with caution in elderly patients: higher susceptibility to adverse events. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Co‑administration with other fluoroquinolones: increased risk of toxicity. - Concurrent systemic corticosteroids: heightened tendon rupture risk. - Combination with other QT‑prolonging agents: potential for serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may diminish antibacterial activity. - Antacids containing magnesium or aluminum: reduce oral absorption (relevant for oral forms). - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.